|Slideshows|April 8, 2020

Pandemic Stress Management

Health professionals' emotional reactions to the COVID-19 pandemic range from numbness, anxiety, fear, and rapid shifts to survivor guilt, helplessness, and feelings of detachment. Here: Stress management tactics and what to expect today and beyond.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Effective Prescription of Exercise for the Treatment of Depression and Anxiety

ByPrerna Gait, MD

August 4th 2026

When Brain Injury and Mental Health Look the Same: The Diagnostic Challenge of Concussion Recovery

ByBrandee Grate-Perry, MSW, LCSWA,Mena Mirhom, MD, FAPA

July 27th 2026

Positive Phase 3 Data for Centanafadine to Treat Comorbid ADHD and Anxiety

ByJessica Walters

July 1st 2026

AI-Driven Biomarker Discovery from Wearables in Neuropsychiatric Research

ByMark Gerstein, PhD

June 5th 2026

SYT-510 for Generalized Anxiety Disorder: Phase 2 Trial Dosing Initiated

ByLeah Kuntz

May 20th 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Register now!

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Pandemic Stress Management

Related Content

Effective Prescription of Exercise for the Treatment of Depression and Anxiety

When Brain Injury and Mental Health Look the Same: The Diagnostic Challenge of Concussion Recovery

Positive Phase 3 Data for Centanafadine to Treat Comorbid ADHD and Anxiety

AI-Driven Biomarker Discovery from Wearables in Neuropsychiatric Research

SYT-510 for Generalized Anxiety Disorder: Phase 2 Trial Dosing Initiated

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jersey City Psychiatry

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Interdisciplinary Consensus Guidelines on Stuttering (Childhood-Onset Fluency Disorder): Addressing Issues in Diagnosis, Treatment, and Unmet Needs

New in Narcolepsy: Pharmacology Updates

New CTx-1301 Data Affirms Pharmacokinetic Profile to Treat ADHD

Morning Rounds: News From August 3-9

New Consensus Guidelines Classify Stuttering as a Brain-Based Disorder